Oppenheimer analyst Justin Kim raised the price target on Cytokinetics (NASDAQ: CYTK) to $107.00 (from $54.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Wall Street bullish on Cytokinetics (CYTK) following positive trial resultsDecember 28, 2023 7:55 AM Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'December 27, 2023 1:43 PM Stocks expected to have increasing option volume: MSTR IOVA CHRS CYTKDecember 27, 2023 9:26 AM Oppenheimer on Cytokinetics (CYTK): 'We stay bullish'December 27, 2023 9:23 AM Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'December 27, 2023 9:21 AM Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'December 27, 2023 9:20 AM B.Riley on Cytokinetics (CYTK): 'Remain Buyers'December 27, 2023 9:18 AM Midday movers: Tesla, Coinbase, and moreDecember 27, 2023 8:11 AM Form 8-K CYTOKINETICS INC For: Dec 27December 27, 2023 7:31 AM Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyDecember 27, 2023 7:30 AM Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyDecember 27, 2023 7:30 AM Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCMDecember 26, 2023 4:01 PM Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic CardiomyopaDecember 26, 2023 4:00 PM